INA-PROACTIVE was a multicenter, prospective, observational cohort study of HIV-positive antiretroviral-naĂŻve and treatment-experienced individuals. No investigational treatment or intervention was used in this study. All participants were managed according to the Indonesian HIV/AIDS Treatment Guideline and the Standard of Care (SoC) in the local clinical setting, with the addition of rapid HIV viral load, CD4 cell count, and syphilis testing.
Data were collected on all participants at baseline and follow-up visits every 6 months (±3-month window period). Additional follow-up data were collected on selected participants who met additional study follow-up criteria.
In this report, the focus was on analyzing pediatric patients. Initially, there were 189 pediatric patients under consideration. However, after careful evaluation, six pediatric patients were excluded from the analysis. These exclusions were based on the presence of certain risk factors associated with acquiring HIV, including engaging in heterosexual or homosexual behaviors, being recipients of blood products. These criteria were applied to ensure a more homogeneous study population for accurate analysis and interpretation of the data.
Those patients are:| ID_patients | Reason |
|---|---|
| 1045601008 | Blood product recipient |
| 1045701004 | Homosexual |
| 1046301006 | Homosexual |
| 1046801001 | Heterosexual |
| 1046901004 | Heterosexual |
In this section, table characteristics is shown for subject characteristics at Enrollment PROACTIVE study.
| Characteristics | N, % |
|---|---|
| Gender | |
| Male | 87 (47.3%) |
| Female | 97 (52.7%) |
| Sites | |
| 510 | 10 (5.4%) |
| 520 | 5 (2.7%) |
| 530 | 36 (19.6%) |
| 540 | 20 (10.8%) |
| 550 | 10 (5.4%) |
| 560 | 11 (5.9%) |
| 570 | 5 (2.7%) |
| 580 | 4 (2.2%) |
| 590 | 10 (5.4%) |
| 600 | 2 (1.1%) |
| 610 | 17 (9.2%) |
| 630 | 8 (4.3%) |
| 650 | 4 (2.2%) |
| 660 | 17 (9.2%) |
| 670 | 5 (2.7%) |
| 680 | 7 (3.8%) |
| 690 | 3 (1.6%) |
| 700 | 10 (5.4%) |
| Birth History: | |
| Delivery method: | |
| Vaginal | 133 (72.3%) |
| Caesarian | 39 (21.2%) |
| Elective | 22 (12.0%) |
| Non-Elective | 17 (9.2%) |
| Birth weight: | |
| < 2500 gram | 11 (7.8%) |
| 2500-3000 gram | 63 (45.7%) |
| >3000 gram | 64 (46.4%) |
| Neonatal status | 172 (93.5%) |
| full term | 165 (89.7%) |
| pre-term | 7 (3.8%) |
| Birth defect: (n=X) | 1 (0.5%) |
| Mother with antenatal care/ ANC History | 137 (74.5%) |
| Mother with ARV during pregnancy | 2 (1.1%) |
| Mother with ARV during delivery | 4 (2.2%) |
| Exclusive breastfed | 134 (72.8%) |
| Prophylaxis ARV | |
| Age (months): | |
| At diagnosis: | 43.4 (1.0 - 206.0) |
| At treatment: | 51.1 (0.0 - 207.0) |
| At enrollment: | 101.6 (15.0 - 210.0) |
| Diagnosis methods: | |
| Rapid diagnostic tests | 79 (42.9%) |
| ELISA | 15 (8.15%) |
| PCR DNA | 1 (0.5%) |
| PCR RNA | 3 (1.6%) |
| Rapid and ELISA | 18 (9.8%) |
| Rapid and PCR DNA | 1 (0.5%) |
| First time HIV was diagnosed: | |
| <2015: | 86 (46.7%) |
| 2015-2017 | 47 (25.5%) |
| 2018-2019 | 23 (12.5%) |
| Reasons for HIV tests: | |
| Own initiative: n (reasons) | 9 (4.9%) |
| Advised by Health Providers: | 169 (91.8%) |
| Opportunistic infection: | 49 (28.9%) |
| Positive mothers: | 71 (41.0%) |
| Non-responsive malnutrition children: | 3 (1.8%) |
| Others: | 46 (27.2%) |
| Tuberculosis history: | |
| Pulmonary tuberculosis: | 71 (38.6%) |
| Extra-pulmonary tuberculosis: | 11 (5.9%) |
| CD4 testing | |
| At diagnosis: | |
| In percentage: (n=X) | |
| >30% | 13 (7.1%) |
| 25-30% | 9 (4.9%) |
| 15-25% | 26 (14.1%) |
| <15% | 34 (18.5%) |
| In absolute | |
| >500 | 72 (39.1%) |
| 350 - 500 | 18 (9.8%) |
| 200 - 350 | 19 (10.3%) |
| <200 | 43 (23.4%) |
| At treatment: | |
| In percentage (n=Y) | |
| >30% | 34 (18.5%) |
| 25-30% | 20 (10.9%) |
| 15-25% | 21 (11.4%) |
| <15% | 18 (9.8%) |
| In absolute: | |
| >500 | 117 (63.6%) |
| 350 - 500 | 12 (6.5%) |
| 200 - 350 | 11 (5.9%) |
| <200 | 26 (14.1%) |
| At enrollment: | |
| In percentage (n= Z) | |
| >30% | 15 (8.15%) |
| 25-30% | 16 (8.7%) |
| 15-25% | 16 (8.7%) |
| <15% | 12 (6.5%) |
| In absolute: | |
| >500 | 99 (53.8%) |
| 350 - 500 | 16 (8.7%) |
| 200 - 350 | 15 (8.15%) |
| <200 | 19 (10.3%) |
| Viral load testing: (<10,000; 10K-100K, >100K) | |
| At diagnosis: | |
| <10.000 | 36 (19.6%) |
| 10K - 100K | 22 (12.0%) |
| >100K | 49 (26.6%) |
| At treatment: | |
| <10.000 | 46 (25.0%) |
| 10K - 100K | 23 (12.5%) |
| >100K | 41 (22.3%) |
| At enrollment: | |
| <10.000 | 22 (12.0%) |
| 10K - 100K | 23 (12.5%) |
| >100K | 37 (20.1%) |
| Clinical diagnosis: | |
| At diagnosis: | |
| 1 | 31 (16.8%) |
| 2 | 29 (15.8%) |
| 3 | 92 (50.0%) |
| 4 | 21 (11.4%) |
| Unknown | 11 (5.9%) |
| At treatment: | |
| 1 | 32 (17.4%) |
| 2 | 29 (15.8%) |
| 3 | 92 (50.0%) |
| 4 | 21 (11.4%) |
| Unknown | 10 (5.4%) |
| At enrollment: | |
| 1 | 80 (43.5%) |
| 2 | 24 (13.0%) |
| 3 | 61 (33.2%) |
| 4 | 17 (9.3%) |
| Unknown | 2 (1.1%) |
| Family Medical History (father, mother, sibling) | |
| HIV | |
| Father | 110 (60.1%) |
| Mother | 173 (94.5%) |
| Siblings | 19 (10.4%) |
| Pulmonary tuberculosis | |
| Father | 38 (24.5%) |
| Mother | 34 (21.9%) |
| Siblings | 8 (5.2%) |
| Diabetes | |
| Father | 1 (0.5%) |
| Mother | 0 (0.0%) |
| Siblings | 0 (0.0%) |
| ARV history: | |
| NaĂŻve | |
| Duration between diagnosis and treatment Initial regimens: | 9 (4.9%) |
| 0-6 months on ARV | |
| Duration between diagnosis and treatment Initial regimens: | 14 (7.6%) |
| Switching regimens: | 3 (21.4%) |
| 6 months – 1 year on ARV | |
| Duration between diagnosis and treatment Initial regimens: | 10 (5.4%) |
| Switching regimens: | 2 (20.0%) |
| >1 year on ARV | |
| Duration between diagnosis and treatment Initial regimens: | 151 (82.1%) |
| Switching to 2nd line: | 41 (27.2%) |
Naive_experience <- read_excel("Naive_experience.xlsx")
ggplot(Naive_experience, aes(x=Var1, y=Freq, fill=Var1)) +
geom_bar(stat = "identity") +
theme_minimal() +
ggtitle("Naive, Experience Group") +
xlab("ARV Treatment Groups") +
scale_x_discrete(labels=c( "1" = "<6 months",
"2" = "6-12 months", "3"=">12months")) +
geom_text(aes(label = Freq), vjust = -0.3, size = 3.5) +
scale_fill_manual(name = "", labels = c("<6 months", "6-12 months",">12months"),
values = c("#22A884FF","#7AD151FF", "#440154FF"))
LTFU_Alive <- read_excel("LTFU_Alive.xlsx")
ggplot(LTFU_Alive, aes(fill=Var1, y=Freq, x=Var2, label=Freq)) +
geom_bar(position="stack", stat="identity") +
geom_text(size = 3, position = position_stack(vjust = 0.5))+
ggtitle("LTFU, Alive Vs ARV Treatment") +
theme_minimal() +
xlab("ARV Treatment Groups") +
scale_x_discrete(labels=c("1" = "<6 months",
"2" = "6-12 months", "3"=">12months")) +
scale_fill_manual(name = "", labels = c("Alive","Death","LTFU"),
values = c("#404688FF","#FDE725FF","#75D054FF"))
## Warning: Removed 2 rows containing missing values (`position_stack()`).
## Removed 2 rows containing missing values (`position_stack()`).
Survival analysis was conducted among individuals categorized into four groups based on the duration of antiretroviral therapy (ART) treatment: naive, <6 months, 6 to 12 months, and >12 months.
fit1 <- survfit(surv_object ~ Categories, data = Surv_ENR)
summary(fit1)
## Call: survfit(formula = surv_object ~ Categories, data = Surv_ENR)
##
## Categories=1
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
##
## Categories=2
## time n.risk n.event survival std.err lower 95% CI
## 819.0000 13.0000 1.0000 0.9231 0.0739 0.7890
## upper 95% CI
## 1.0000
##
## Categories=3
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
##
## Categories=4
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 43 151 1 0.993 0.0066 0.981 1.000
## 274 150 1 0.987 0.0093 0.969 1.000
## 383 149 1 0.980 0.0114 0.958 1.000
## 392 148 1 0.974 0.0131 0.948 0.999
## 518 146 1 0.967 0.0146 0.939 0.996
## 552 145 1 0.960 0.0159 0.929 0.992
## 567 144 1 0.954 0.0172 0.920 0.988
## 708 143 1 0.947 0.0183 0.912 0.983
ggsurvplot(fit1, data = Surv_ENR, pval = TRUE, xlab="Duration of Study (Days)")
By convention, vertical lines indicate censored data, their corresponding x values the time at which censoring occurred.
The log-rank p-value of 0.77 indicates a non-significant result if consider p < 0.05 to indicate statistical significance. In this study, none of the duration of ART treatment were significantly superior, although Categories 1(Naive) and Categories 3(6-12 months) are doing better until end of study.
Surv_ENR$SEX_E1_C2 <- factor(Surv_ENR$SEX_E1_C2 ,
levels = c("1", "2"),
labels = c("Male", "Female"))
fit2 <- survfit(surv_object ~ SEX_E1_C2, data = Surv_ENR)
summary(fit2)
## Call: survfit(formula = surv_object ~ SEX_E1_C2, data = Surv_ENR)
##
## SEX_E1_C2=Male
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 383 87 1 0.989 0.0114 0.966 1.000
## 392 86 1 0.977 0.0161 0.946 1.000
## 518 84 1 0.965 0.0196 0.928 1.000
## 552 83 1 0.954 0.0226 0.910 0.999
## 708 82 1 0.942 0.0251 0.894 0.993
##
## SEX_E1_C2=Female
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 43 96 1 0.990 0.0104 0.969 1.000
## 274 94 1 0.979 0.0147 0.951 1.000
## 567 93 1 0.969 0.0179 0.934 1.000
## 819 92 1 0.958 0.0206 0.919 0.999
ggsurvplot(fit2, data = Surv_ENR, pval = TRUE, xlab="Duration of Study (Days)")
Similar to the previous plot, which did not indicate statistical significance, the current plot also shows a non-significant log-rank p-value of 0.63. This suggests that there are no significant differences in survival between males and females in this study.
# Fit a Cox proportional hazards model
fit.coxph <- coxph(surv_object ~ Categories + SEX_E1_C2,
data = Surv_ENR)
ggforest(fit.coxph, data = Surv_ENR)
Hazard ratio of 0.73 for sex groups tells that female patients have a reduced risk of dying compared to male patients (which served as a reference to calculate the hazard ratio). Using this model, tells that group of duration ART treatment and sex group does not significantly influence the patients’ risk of death in this study.